Upstream Bio UPB
NASDAQ UPB
$5.04 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Upstream Bio (UPB) Return on Equity [ROE] (2024 - 2026)

Updated

Upstream Bio (UPB) recorded Return on Equity [ROE] of -54.44% in Q2 2026, down 30.00 percentage points from -24.44% a year earlier and down 5.76 percentage points from the prior quarter.

Analysis

Upstream Bio (UPB) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Upstream Bio reported Return on Equity [ROE] of -35.43%, up 2.43 percentage points from FY2024.

  • Across earlier years, Return on Equity [ROE] came in at -37.86% in FY2024.
  • Per Business Quant, the preceding three quarters came in at -48.69% (Q1 2026), -39.93% (Q4 2025) and -31.03% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Upstream Bio 276.05 Mn 276.05 Mn -3.29 Mn -54.44%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -54.44%
Mar 31, 2026 -48.69%
Dec 31, 2025 -39.93%
Sep 30, 2025 -31.03%
Jun 30, 2025 -24.44%
Mar 31, 2025 -17.29%
Dec 31, 2024 -42.41%
API Access

Upstream Bio Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=UPB&period=max&api_key=YOUR_API_KEY